Intra-Articular Allocetra for Knee Osteoarthritis
Official title: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
Run by Enlivex Therapeutics Ltd. · NCT07580716 · Data updated 2026-11-12
This study tests whether injecting Allocetra into the knee can help people with moderate-to-severe knee osteoarthritis compare to a placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 64 Years and up |
| Sex | All |
| Enrollment | 182 (estimated) |
| Sponsor | Enlivex Therapeutics Ltd. Industry-sponsored |
| Locations | 17 sites (Longwood, Florida and 16 other locations) |
| Status | Recruiting |
| Started | May 1, 2026 |
| Main results expected | February 2027 |
| Study ends | April 2028 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT07580716 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 64 and older with radiographic KL grade 2–3 knee OA who have not adequately responded to at least two OA therapies.
✕Probably not a fit
Patients with lower limb OA not meeting KL criteria or who have contraindications to intra-articular injections may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase IIb, multicenter, randomized, double-blind study compares three ultrasound-guided intra-articular Allocetra injections to placebo in adults aged 64 and older with radiographically confirmed primary knee OA who have not adequately responded to at least two OA therapies. Participants receive injections on Days 0, 14, and 28 and are followed for 12 months to assess pain and function. Allocetra consists of modified allogeneic peripheral blood mononuclear cells designed to promote cartilage-friendly inflammation resolution. The trial seeks to determine if Allocetra can reduce knee pain and improve function compared with placebo. Enrollment occurs at selected sites in Florida and Louisiana.
Why it matters
Potential benefit: If successful, Allocetra could reduce knee pain and improve joint function for people with knee OA.
How similar studies have gone: Previous cell-based approaches for OA have shown mixed results; this trial builds on a growing interest in immunomodulatory therapies for joint inflammation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants must meet all of the inclusion criteria listed below to be eligible for the study: 1. Age 64 years or above. 2. Diagnosis of primary femorotibial knee OA. 3. Radiographic evidence of knee OA defined as Kellgren-Lawrence (KL) grade 2 or 3 in the index knee. 4. Participants who are intolerant to, or have failed to adequately respond to at least 2 OA therapies. 5. Index knee pain assessed during the screening period and following wash-out of pain medications. 6. Willingness to abstain from prohibited medications/treatments during the trial. 7. Women who are postmenopausal (≥12 months natural amenorrhea without alternative cause) or surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy). 8. Male participants with partners of childbearing potential, who are not surgically sterile (vasectomy) for at least 6 months prior to randomization, must use condoms with spermicide in addition to their partner's contraception from randomization and for 90 days after last dose. Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria: 1. Severe or end-stage osteoarthritis of the index knee. 2. Clinically significant structural abnormalities or instability of the index knee. 3. Recent major injury, surgical procedure, or intra-articular treatment in the index knee. 4. Any known history of infection or tumor of the index knee, or active infection at the intended injection site. 5. Any known history of inflammatory arthropathy or crystal-deposition disease. 6. Any severe systemic cartilage, bone, or musculoskeletal disorder that may interfere with study outcomes. 7. Clinically significant widespread pain syndromes. 8. Immunosuppressive therapy, clinically significant immunodeficiency, or active infection. 9. Body Mass Index (BMI) \>40 kg/m² 10. Use of medications that may interfere with pain assessment or study outcomes. 11. Known coagulopathy or use of anticoagulant/antiaggregant medication. 12. Significant uncontrolled systemic disease or clinically significant findings on screening laboratory tests or physical examination.
Where it's running
-
Future Medical Research
Longwood, Florida, United States Recruiting -
South Florida Research Phase I-IV
Miami, Florida, United States Recruiting -
DelRicht Research @ Touro Medical Center
New Orleans, Louisiana, United States Recruiting -
Oakland Medical Research
Troy, Michigan, United States Recruiting -
Sanos Clinic Gandrup
Gandrup, Denmark Recruiting -
Sanos Clinic Herlev
Herlev, Denmark Recruiting
Show 11 more locations
-
Sanos Clinic Vejle
Vejle, Denmark Recruiting -
NZOZ Bif-Med. s.c
Bytom, Poland Recruiting -
Vita Longa Sp. z o.o.
Katowice, Poland Recruiting -
Medyczne Centrum Hetmańska
Poznan, Poland Recruiting -
Reumedika sp. z o.o.
Poznan, Poland Recruiting -
DC-MED Michal Kowalski S.K. Swidnica
Swidnica, Poland Recruiting -
Etg Justmed
Warsaw, Poland Recruiting -
Etg Warszawa
Warsaw, Poland Recruiting -
Migre Polskie Centrum
Wroclaw, Poland Recruiting -
Centrum Medyczne PLEJADY
Krakow, Poland Not yet recruiting -
DC-MED Michal Kowalski S.K. Radom
Radom, Poland Not yet recruiting
Study contacts
- Study coordinator: Lior Binder
- Email: lior@enlivex.com
- Phone: +972-54-8054599
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cold and compression after total knee replacement
This tests whether using a cold-compression device after total knee replacement reduces pain compared with standard care for adults with primary osteoarthritis.
-
Effects of virtual reality on walking in adults with knee osteoarthritis
This study tests how immersive virtual reality environments—designed to feel safe or to provoke fear—affect walking and worry about movement in adults 50 and older with knee osteoarthritis and in healthy peers.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Autologous adipose-derived stem cell injections for knee osteoarthritis
We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.
-
Preoperative Multimorbidity and Functional Recovery After Total Knee Arthroplasty
This study tests whether higher burden of preoperative multimorbidity affects functional recovery after knee replacement in adults with knee osteoarthritis.
-
Cartilage biomarker response to acute loading in knee OA by antiresorptive treatment status
Researchers will test whether a 30-minute treadmill walk changes cartilage biomarkers in postmenopausal women with knee osteoarthritis, comparing those on denosumab, bisphosphonates, and those not on antiresorptives.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.